|
Dec 27
|
Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
|
|
Dec 26
|
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
|
|
Dec 15
|
11 Most Promising Biotech Stocks to Buy According to Analysts
|
|
Dec 7
|
Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
|
|
Dec 1
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 29
|
Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND
|
|
Nov 4
|
12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds
|
|
Nov 3
|
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
|
Nov 3
|
Q3 2023 Cytokinetics Inc Earnings Call
|
|
Nov 3
|
Cytokinetics, Incorporated (NASDAQ:CYTK) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Cytokinetics Inc (CYTK) Reports Q3 2023 Financial Results
|
|
Nov 2
|
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
|
|
Nov 2
|
Cytokinetics Reports Third Quarter 2023 Financial Results
|
|
Nov 2
|
Wall Street Analysts Believe Cytokinetics (CYTK) Could Rally 75.5%: Here's is How to Trade
|
|
Sep 9
|
10 Biotech Stocks with Biggest Upside
|
|
Sep 7
|
Cytokinetics to Participate in Upcoming Investor Conferences
|
|
Sep 6
|
Cytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
|
|
Aug 8
|
15 Worst Performing Biotech Stocks in 2023
|
|
Aug 3
|
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 3
|
Cytokinetics Reports Second Quarter 2023 Financial Results
|